Phaseline

Companies › GI Innovation

GI Innovation: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 5 Phase 1, 2 Phase 2; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GI-102
CD80-IgG4 Fc-IL2v3 fusion protein
CD80Phase 2Cancer Survivors; Advanced Solid Tumor; Metastatic Castration-resistant Prostate Cancer (mCRPC)Apr 2027
GI-108
Anti-CD73-IgG4 Fc-IL-2v bispecific fusion protein
CD73, IL2RAPhase 1Advanced Solid TumorFeb 2027
GI-101–Phase 1Advanced Solid TumorJun 2028
GI-101A–Phase 1Advanced Solid TumorJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07363057GI-102Phase 2Cancer SurvivorsOncologyMay 2026
NCT07363057GI-102Phase 2Cancer SurvivorsOncologyMay 2026
NCT07172802GI-108Phase 1Advanced Solid TumorOncologyFeb 2027
NCT05824975GI-102Phase 1Advanced Solid TumorOncologyApr 2027
NCT04977453GI-101Phase 1Advanced Solid TumorOncologyJun 2028
NCT04977453GI-101APhase 1Advanced Solid TumorOncologyJun 2028
NCT07871435GI-102Phase 1Metastatic Castration-resistant Prostate Cancer (mCRPC)OncologyMar 2029

Targets

CD80 (1) CD73 (1) IL2RA (1)

Companies with the same targets

Bristol-Myers Squibb Coya Therapeutics AP Biosciences Nektar Therapeutics Regeneron Pharmaceuticals Mural Oncology PolTREG Synthekine AgonOx CellTrans

Companies built like this

Kumquat Biosciences Vividion Therapeutics Eikon Therapeutics Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) RayzeBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.